Rhenman & Partners Asset Management AB Acquires 137,000 Shares of LivaNova PLC $LIVN

Rhenman & Partners Asset Management AB grew its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 258.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 190,000 shares of the company’s stock after acquiring an additional 137,000 shares during the period. Rhenman & Partners Asset Management AB’s holdings in LivaNova were worth $11,691,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of LIVN. Hantz Financial Services Inc. grew its position in shares of LivaNova by 159.9% during the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after acquiring an additional 267 shares during the period. State of Wyoming bought a new stake in shares of LivaNova during the 2nd quarter valued at $31,000. EverSource Wealth Advisors LLC grew its position in shares of LivaNova by 998.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after acquiring an additional 639 shares during the period. Quarry LP bought a new stake in shares of LivaNova during the 3rd quarter valued at $36,000. Finally, Covestor Ltd grew its position in shares of LivaNova by 108.6% during the 4th quarter. Covestor Ltd now owns 753 shares of the company’s stock valued at $46,000 after acquiring an additional 392 shares during the period. Institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Stifel Nicolaus set a $80.00 price objective on shares of LivaNova in a research report on Wednesday, February 25th. Needham & Company LLC lifted their target price on shares of LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Weiss Ratings upgraded shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research note on Thursday, May 7th. Robert W. Baird lowered their target price on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Finally, Barclays lifted their target price on shares of LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. Six analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $79.38.

Insider Buying and Selling at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total value of $136,350.00. Following the sale, the director owned 7,228 shares in the company, valued at $547,521. The trade was a 19.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.35% of the company’s stock.

LivaNova Stock Down 0.7%

LIVN opened at $79.39 on Friday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.11 and a current ratio of 1.33. LivaNova PLC has a fifty-two week low of $41.01 and a fifty-two week high of $80.74. The firm’s fifty day moving average is $69.08 and its 200 day moving average is $65.77. The stock has a market cap of $4.36 billion, a price-to-earnings ratio of 40.71 and a beta of 0.88.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.13. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The company had revenue of $362.26 million for the quarter, compared to analysts’ expectations of $346.05 million. During the same quarter in the previous year, the company earned $0.88 EPS. LivaNova’s revenue for the quarter was up 14.3% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, sell-side analysts forecast that LivaNova PLC will post 3.72 earnings per share for the current fiscal year.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.